Member Info for ChrisToffer

And is a share price built on thin air what we really want?

Can you explain what you mean there Pete? How did he burn money that is needed for manufacturing lines by not revealing anything new?

Lots of nonsense has been written on this board today on the way up and the way back down. Nothing has changed. That is what the RNS says.

To reiterate what Piper posted

“ Hello

Thank you for your message.

Our current capacity for lateral flow tests at Alva is 100,000 tests per week. We are currently in the process of increasing that to 200,000 tests per week and looking at options to further increase to 500,000 tests per week.

Our capacity in Littleport is currently just under 50,000 tests per day. We are currently looking to increase that to 100,000 per day.

That's up to 26m a year in Alva and 36.5 in Littleport. The consortium is working together to produce the POC test and then each manufacturer within the consortium will be able to commercialise it as much as they want.

The priority will be government orders however there will still be a huge international market so 50m test a year is achievable!

Uallmakeitup that us utter bolox! Speak to a paramedic or anyone who has witnessed this disease first hand and they'll paint a much bleaker picture than the 100 people you know. People with underlying health issues and in care homes are exposed because of the nature of this virus which by all accounts will rewrite medical books.

Notnow, the amendment to the NIHR trial approval stated that the initial hospital trial patients who were discharged during the 14 day trial period continued to use the nebuliser at home. I think that was a contributing factor to getting home trial apporoval.

That's fantastic Dave! Certainly beats my back of a fag packet speadsheet on the timelines ha!

Look up the panorama video treetop, it actually shows a lady taking using a nebuliser.

Additionally, there will be a lot of international focus on these trials from proponents of Interferon as a treatment for the virus. A lot of reports have indicated that it is a viable treatment without backing those claims up with the level of evidence that this trial aims to deliver.

Hi treetop, they had a bid weekend of media focus a few weeks back (on panorama etc.) It doesn't change the price of bread though because of the nature of the blinded trial. No point in shouting about anything yet because they need to prove it works. If successful, in this current climate the results should speak for themselves!

Spot on Demon, the impact of this virus is gonna be felt for years and one of the most obvious things to come out of it is a lack of mass diagnostic capability. There is huge market growth now because of that so there i will be a slice for anyone who can deliver a reliable test (or large scale testing capability) in a reasonable time frame.

Thats old news Johnny. That is the Quotient machine that is being set up by Open Orphan in East London. 3000 tests a day priced between 70 and 150 quid. They only have like 12 machines available. Can you imagine the logistics of getting all those blood samples to 12 machines?

Sam you can not compare ODX to any of those other shares. The AIM ones are involved with different tests and the big players are just that! If you're invested here it is always at risk of one of the big boys getting ahead of the game, however they're not known for having large market share in diagnostics which is one of the reasons why COVID testing stocks have a huge opportunity in this current climate. P
With government backing here and the development of the track and trace app which Abbington have (pretty much) confirmed will be linked to at home antibody tests, I think Omega are still in a very strong position. The RTC still has to deliver though!

Spot on SC! Yes the share price is derived from the price of the share and the number of shares, however a low SNG market cap relative to its' peers would suggest more upside in the event of good news. GDR (developing test assays) was in a similar position a few weeks back and then rocketed to over 2 quid on very little to no news.

All Ghia has done the last few days is keep an open mind and try to actually understand Nolupus' reasoning. I've dismissed that reasoning myself in the past by the way.
They were actually having a sensible conversation about the merits of other treatments and what stages of development they are at. That does help inform our decisions. Despite any earlier contributions, I don't find conspiracy theories about people with double accounts and coming out with the usual 'you wouldn't wanna be out if this over the weekend' very helpful at all.

You're referring to Remdesivir et al.?

Thanks Ghia, I did have a read over the document you posted yesterday on the AntiCovir treatment. Fairly technical but I took that as a very positive sign that SNG001 is on the right track. I believe the Faron treatment is via IV so will target hospital patients? The AVCT development this morning I found very interesting also and shows a lot of promise (though it still needs to be validated which could take quite some time).

I'm not aware of any treatments outside of the inerferon family (for want of a better word) of that are so far along in the approval process?

Hi Nolupus, can you elaborate on what other treatments you believe SNG are behind in development/trials? Is there anyone that is developing a treatment for covid19 that has moved beyond stage 2 trials?

Black and White would suggest a conclusive answer. Richard Marsden is quoted as saying that conclusive is a strong word. This suggested to me at the time that the result of the trials is not binary.

The main objective of the trial, as per the EU trial register is,
'To assess whether SNG001 is well tolerated, and can prevent or accelerate recovery of lower respiratory tract illness in patients with SARS-CoV-2 infection.'

Is it safe? I don't think it would have been approved for home use if it wasn't.

Does it prevent or accelerate recovery of lower respiratory tract illness? It's highly unlikely that this or any drug will 100% prevent patients from developing lower respiratory tract illness. If it does, then the trial will have a conclusive answer and we could have a miracle drug on our hands - not to mention the fact we'll all be rich.

However, if we look at it realistically and acknowledge that no individual drug is going to be the answer to this awful virus, then the outcome of the trial will be to assess how much it helps. If it does help then it will likely move to phase 3 trials and hopefully SNG will have enough supporting data to get it approved for emergency use, therefore start to commercialise it.

As (if) it is rolled out to the wider population the understanding of how useful it is will grow.

I think it is fair to assume that the drug will be proven as safe or else it wouldn't have been approved for home use. From all of the great research that others on this board have posted, there are strong signs that there are benefits of using interferon as a treatment for the virus. The question on what constitutes a successful trial is not a yes or no, but rather how many patients it can help and how much it helps patients at different stages of the virus. I think of it almost like a scale where the more patients it helps and the more stages of the virus that it can be administered- the more successful the trial is and the more this share price will rise.

We could walk the same path as Gilead however the double blind placebo trial that SNG are currently conducting is of the highest standard and if successful will be the basis for all the other approvals, therefore Emergency Use Approval would not be instead/or before UK approval but rather, off the back of it.

EUA also doesn't necessarily negate the need for a phase 3 trial (though it would certainly help to deliver one). As in the case of Gilead, it also seems to have allowed them to start generating revenue through licencing.